The monitoring period is an important part of every Spravato treatment session. Unlike many medications that can be taken at home, Spravato, or esketamine nasal spray, is administered in a certified healthcare setting because it can temporarily affect alertness, perception, coordination, and blood pressure. After receiving the medication, patients remain under observation while the healthcare team monitors their response and makes sure they are stable before leaving.
Spravato can produce temporary effects such as sedation, dissociation, dizziness, nausea, and increases in blood pressure. Some patients may also experience changes in perception or awareness shortly after administration.
The monitoring period allows healthcare professionals to observe these effects in a controlled setting. The FDA requires patients to be monitored for at least two hours after Spravato administration and evaluated before discharge. This safety process is part of the Spravato REMS requirements.
Monitoring does not necessarily mean that patients will experience significant side effects. Instead, it provides an opportunity for the spravato treatment team to identify and respond to changes if they occur.
After the nasal spray is administered, you remain at the treatment center rather than immediately returning home. The healthcare team observes you during the recovery period and monitors your overall condition.
You may notice temporary changes in how you feel or perceive your surroundings. Some people experience a dreamlike or disconnected sensation, while others may feel sleepy or lightheaded. These effects can vary from one treatment session to another.
At Scottsdale TMS & Spravato, patients receive supervised treatment followed by a dedicated observation period. The clinical team monitors your response and provides support while the effects of the medication gradually decrease.
During the spravato monitoring period, your provider pays attention to your physical and mental response to treatment. Blood pressure is an important part of monitoring because Spravato can cause temporary increases.
The team may also observe for signs of sedation, dissociation, dizziness, changes in awareness, or breathing difficulties. Your condition is assessed throughout the recovery period rather than relying on a single check immediately after administration.
The purpose is to determine whether you are clinically stable before leaving the treatment setting.
The FDA prescribing information requires monitoring for at least two hours after Spravato administration. The healthcare provider then determines whether you are stable enough to leave.
Two hours is the minimum monitoring requirement, not necessarily a guarantee that every patient will have exactly the same experience. The length of the visit can depend on your response to treatment and whether additional observation is needed.
Patients should plan their schedules accordingly and avoid arranging important activities immediately after an appointment.
The effects experienced during recovery can differ between individuals. Some patients may feel relatively comfortable, while others notice more pronounced temporary sensations.
Possible effects include:
These effects are monitored because Spravato can temporarily affect your ability to think clearly, coordinate movement, or respond normally to your surroundings.
If you experience something that concerns you, tell the healthcare team. Communicating what you are experiencing helps your providers determine whether additional monitoring or care is necessary.
Patients should not drive or operate machinery after receiving Spravato. The medication can temporarily affect attention, judgment, alertness, and coordination.
The FDA prescribing information states that patients should not drive or operate machinery until the next day after a restful sleep. Patients also need to arrange transportation home after treatment.
Planning transportation before your appointment can make the process easier and prevent last-minute complications.
Before discharge, the healthcare provider evaluates whether you have recovered sufficiently from the immediate effects of treatment. The goal is to make sure you are clinically stable and ready to leave the supervised setting.
You may still feel tired after the formal observation period, so planning a quiet remainder of the day can be helpful. Follow any individualized instructions provided by your treatment team.
Dr. Michael Vines and Our Team at Scottsdale TMS & Spravato can explain what to expect during the monitoring period and answer questions about your individual treatment experience.
The Spravato monitoring period is a required part of treatment designed to protect patients while the temporary effects of esketamine wear off. After administration, patients remain under professional observation for at least two hours while their blood pressure, alertness, and overall response are monitored.
Understanding this process can help you prepare for your appointments and know why you cannot simply leave after receiving the nasal spray. Scottsdale TMS & Spravato provides supervised treatment and post-treatment monitoring to help patients receive esketamine within an appropriate clinical setting.
Dr. Vines has practiced psychiatry in Arizona for for over 25 years and has experience working with diverse populations that include children, adolescents, adults, geriatrics, SMI patients, and the chemically dependent.
August 8, 2026
